ReviewFrontiers in immunology2026
Toward mechanistic endotyping in allergic rhinitis: a State-Place-Time framework for appraising nasal tissue evidence.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic rhinitis (AR) heterogeneity is usually described by sensitization, symptom burden, or inflammatory profiles, but these descriptors do not establish which mechanism operates in a particular nasal mucosa. This critical narrative review proposes a State-Place-Time framework that evaluates cellular programs together with their anatomical setting and exposure-related response phase. The framework distinguishes descriptive tissue states from candidate mechanistic modules, measurable mechanistic endotypes, and clinically actionable endotypes. These are operational definitions for this review, rather than a validated classification. Five overlapping examples are examined: IgE-FcϵRI effector activity, late-phase type 2 amplification, barrier-repair dysfunction, separable sensory, vascular, and secretory outputs, and putative stromal maintenance. An author-derived conceptual matrix summarizes human evidence, spatial localization, timing/recurrence, matched perturbation, accessible measurement, and clinical utility; it does not provide an evidence score or patient assignment rule. Human intervention supports IgE-pathway dependence, but this does not establish a validated nasal tissue endotype for treatment selection. Late-phase cytokine responses and epithelial abnormalities are supported by human observations and functional systems, while their stability and predictive utility remain incompletely established. Stromal maintenance remains a hypothesis, with important limits from nasal polyposis sampling and inferred communication. The framework complements existing clinical and inflammatory classifications by identifying missing links and testable alternatives. Progress toward clinical use requires reproducibility within patients, analytical and external validation, and incremental value beyond routine assessment; treatment-selection claims additionally require evidence of differential treatment benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.